Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era

Int J Hematol. 2010 Mar;91(2):342-4; author reply 345-6. doi: 10.1007/s12185-010-0522-z. Epub 2010 Feb 27.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / adverse effects
  • Female
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Core Antigens / immunology*
  • Hepatitis B* / diagnosis
  • Hepatitis B* / epidemiology
  • Hepatitis B* / immunology
  • Humans
  • Immunocompromised Host
  • Lymphoma* / complications
  • Lymphoma* / drug therapy
  • Lymphoma* / epidemiology
  • Male
  • Middle Aged
  • Rituximab
  • Seroepidemiologic Studies

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens
  • Rituximab